Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- No Complaints Received So Far for Penalty Fee Cuts: MHLW Official
June 10, 2014
- Japan Sees 53-Month Designation Lag, 54-Month Approval Lag for Orphan Drugs
June 9, 2014
- MHLW Designates 20 Products including Allegra FX as Drugs Requiring Face-to-Face Consultations
June 9, 2014
- Researchers Aiming to Craft Guide for Ultra-Orphan Drug Development
June 9, 2014
- JRCS to Use Nucleic Acid Testing on Individual Samples of Donated Blood: PAFSC Committee
June 9, 2014
- MHLW Rejects Proposal to Abolish Market Expansion Re-Pricing Rule
June 6, 2014
- LDP Members with Vested Interests to Oppose Annual Drug Price Revision
June 6, 2014
- MHLW, Pharma Officials Take to Nagata-cho in Crusade against Yearly NHI Price Revision
June 6, 2014
- MHLW Gets Ball Rolling on OTC Diagnostics Deregulation
June 5, 2014
- MHLW Orders Revision of Package Inserts to Urge Caution in Concurrent Use of ARBs and ACE Inhibitors
June 5, 2014
- MOF Budget Examiner Calls for Revising Price-Gap Rule for Key Premium
June 4, 2014
- MHLW Should Clear Hurdles, Revise NHI Prices Annually: MOF Budget Examiner
June 4, 2014
- Gov’t to Discuss Further Reforms of Mixed Care System, Commit to Deregulation: PM Abe
June 4, 2014
- “Difficult” to Include Annual NHI Price Revision in Govt Blueprint: Minister
June 4, 2014
- LDP Members Voice Mixed Opinions on Active Recommendation for HPV Vaccines
June 3, 2014
- TPP Talks over IP Rights Hitting Snag: Cabinet
June 3, 2014
- MHLW Partially Agrees with Gov’t Panel’s Reason for Creation of New Mixed Care Rule
June 2, 2014
- Fiscal System Council Renews Call for Annual NHI Price Revision, MHLW Still Guarded
June 2, 2014
- PAFSC’s First Committee Backs Approval of LEO Pharma’s Ointment for Psoriasis Vulgaris, Shire Japan’s Gaucher’s Disease Drug
June 2, 2014
- MHLW Announces Addition of 9 APIs/11 Products to NHI Price List Including Takeda’s Takelda
June 2, 2014
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…